These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6197639)

  • 41. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
    Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
    Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tardive dyskinesia: a biological appraoch.
    Barbaccia ML; Trabucchi M
    Prog Clin Biol Res; 1980; 39():181-93. PubMed ID: 6105670
    [No Abstract]   [Full Text] [Related]  

  • 43. Vasoactive peptides. State-of-the-art review.
    Said SI
    Hypertension; 1983; 5(2 Pt 2):I17-26. PubMed ID: 6186605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Neurotransmitters and neuropeptides].
    Płaźnik A; Puciłowski O; Kostowski W
    Pol Tyg Lek; 1983 Jun; 38(26):811-5. PubMed ID: 6196765
    [No Abstract]   [Full Text] [Related]  

  • 45. Dopamine and the action of opiates: a reevaluation of the dopamine hypothesis of schizophrenia. With special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia.
    Schmauss C; Emrich HM
    Biol Psychiatry; 1985 Nov; 20(11):1211-31. PubMed ID: 2996642
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose naloxone in tardive dyskinesia.
    Lindenmayer JP; Gardner E; Goldberg E; Opler LA; Kay SR; van Praag HM; Weiner M; Zukin S
    Psychiatry Res; 1988 Oct; 26(1):19-28. PubMed ID: 3070611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Neuropeptides as neurotransmitter (author's transl)].
    Kito S; Itoga E; Kishida T
    No To Shinkei; 1980 May; 32(5):453-68. PubMed ID: 6156692
    [No Abstract]   [Full Text] [Related]  

  • 48. The effect of neuropeptides on neurotransmitter biochemistry in the CNS.
    Vaughan PF
    Cell Mol Biol; 1982; 28(4):369-82. PubMed ID: 6182996
    [No Abstract]   [Full Text] [Related]  

  • 49. Tardive dyskinesia successfully treated with alprazolam.
    Jordan HW; Williams BC
    J Natl Med Assoc; 1990 Sep; 82(9):673-5. PubMed ID: 2213917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of neuropeptide release.
    Iversen LL; Lee CM; Gilbert RF; Hunt S; Emson PC
    Proc R Soc Lond B Biol Sci; 1980 Oct; 210(1178):91-111. PubMed ID: 6159655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peptides as putative excitatory neurotransmitters: carnosine, enkephalin, substance P and TRH.
    Nicoll RA; Alger BE; Jahr CE
    Proc R Soc Lond B Biol Sci; 1980 Oct; 210(1178):133-49. PubMed ID: 6159651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Case report of adverse effect of reserpine on tardive dyskinesia.
    Donatelli A; Geisen L; Feuer E
    Am J Psychiatry; 1983 Feb; 140(2):239-40. PubMed ID: 6129810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Schizophrenia and tardive dyskinesia: is schizophrenia also a "denervation hypersensitivity"?
    Kapit RM
    Med Hypotheses; 1977; 3(5):207-10. PubMed ID: 904502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pathophysiologic basis of tardive dyskinesia.
    Baldessarini RJ
    Psychopharmacol Bull; 1978 Oct; 14(4):79-81. PubMed ID: 30114
    [No Abstract]   [Full Text] [Related]  

  • 55. [Physiopathology and treatment of tardive dyskinesia].
    Cai N; Song TS
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):252-5. PubMed ID: 3000711
    [No Abstract]   [Full Text] [Related]  

  • 56. [Antipsychotic efficacy of neuroleptic neuropeptides in schizophrenia. Review of clinical data].
    Verhoeven VM
    Encephale; 1987; 13(6):349-56. PubMed ID: 2453339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tardive dyskinesia in dopa-responsive dystonia: a reappraisal of the dopamine hypothesis of tardive dyskinesia.
    de la Fuente-Fernández R
    Neurology; 1998 Apr; 50(4):1134-5. PubMed ID: 9566407
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
    Alpert M; Friedhoff AJ; Diamond F
    Adv Neurol; 1983; 37():253-8. PubMed ID: 6134444
    [No Abstract]   [Full Text] [Related]  

  • 59. Peptides as neurotransmitters: focus on the enkephalins and endorphins.
    Miller RJ
    Pharmacol Ther; 1981; 12(1):73-108. PubMed ID: 6166953
    [No Abstract]   [Full Text] [Related]  

  • 60. [Vestibulo-protective properties of regulatory peptides].
    Drozd IuV; Iasnetsov VV; Shashkov VS
    Biull Eksp Biol Med; 1988 Jul; 106(7):50-2. PubMed ID: 2456793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.